Supriya Lifescience Ltd

Tue 1/09/2026,15:51:59 | NSE : SUPRIYA

₹803.154.85 (0.61%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 798.30

Previous Close

₹ 798.30

Volume

105067

Mkt Cap ( ₹ Cr)

₹ 6463.98

High

₹ 809.00

Low

₹ 795.50

52 Week High

₹ 1085.00

52 Week Low

₹ 545.50

Book Value Per Share

₹ 151.81

Dividend Yield

0.00

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Supriya Lifescience Ltd

Your Vote -

Buy

66.29%

Hold

5.62%

Sell

28.09%

66.29%

89 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Supriya Lifescience Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Supriya Lifescience has declared 50% Final dividend for the financial year March 2026

    29 Aug 2026, 8:50PM Supriya Lifescience Ltd. on Wednesday, 27 May 2026, has announced Final dividend of 50 percent on Equity Share, to its shareholders holding shares on

  • Supriya Lifescience - Copy of Newspaper Publication

    27 Aug 2026, 5:16PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication

  • Supriya Lifescience - Record Date For Determining Members Eligible To Receive Dividend For The Financial Year 2025-26.

    26 Aug 2026, 5:29PM Enclosed herewith is the intimation of record date for determining list of members eligible to receive dividend for FY 2025-26.

  • Supriya Lifescience - Record Date

    26 Aug 2026, 5:29PM Supriya Lifescience Limited has informed the Exchange that Record date for the purpose of Dividend is 04-Sep-2026.

  • Supriya Lifescience - Shareholders meeting

    22 Aug 2026, 1:06PM Supriya Lifescience Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange reg

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    22 Aug 2026, 1:08PM Scrutinizer's Report and Voting Results for Postal ballot conducted by the Company are enclosed herewith.

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    22 Aug 2026, 1:05PM Voting Results and Scrutinizer's Report for the Postal ballot conducted by the Company are enclosed herewith.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    18 Aug 2026, 4:38PM Earnings Call Transcript of the Earning Call for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Aug 2026, 4:38PM Supriya Lifescience Limited has informed the Exchange about Transcript

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    14 Aug 2026, 5:21PM Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Aug 2026, 5:21PM Supriya Lifescience Limited has informed the Exchange about Link of Recording

  • Supriya Lifescience - Copy of Newspaper Publication

    14 Aug 2026, 5:15PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication

  • Supriya Lifescience - Press Release

    13 Aug 2026, 11:27PM Supriya Lifescience Limited has informed the Exchange regarding a press release dated August 13, 2026, titled ""Press Release for Unaudited Financial

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    13 Aug 2026, 11:27PM Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.

  • Supriya Lifescience - Updates

    13 Aug 2026, 7:38PM Supriya Lifescience Limited has informed the Exchange regarding 'Unaudited Financial Results for Quarter ended June 30, 2026'.

  • Supriya Lifescience - Investor Presentation

    13 Aug 2026, 7:28PM Supriya Lifescience Limited has informed the Exchange about Investor Presentation

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Investor Presentation

    13 Aug 2026, 7:28PM Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.

  • Supriya Lifescience - Unaudited Financial Results For The Quarter Ended June 30, 2026.

    13 Aug 2026, 6:48PM Unaudited Financial Results for the quarter ended June 30, 2026 is enclosed.

  • Supriya Lifescience - Outcome of Board Meeting

    13 Aug 2026, 6:40PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13, 2026

    13 Aug 2026, 6:36PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Aug 2026, 9:45PM Intimation of the Earnings call for Unaudited Financial Results of the Company for the quarter ended June 30, 2026 is enclosed herewith.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 9:45PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Board Meeting Intimation for Unaudited Financial Results For Quarter Ended June 2026

    6 Aug 2026, 6:23PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider

  • Supriya Lifescience - Copy of Newspaper Publication

    23 Jul 2026, 9:32AM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication

  • Supriya Lifescience - Shareholders meeting

    21 Jul 2026, 4:57PM Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    21 Jul 2026, 4:53PM Please Find Attached Postal Ballot Notice of Supriya Lifescience Limited.

  • Supriya Lifescience has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    18 Jul 2026, 7:40PM As of June 2026, 68.30% is owned by Indian Promoters and 31.70% by Public. <p align=justify> Institutional holds 11.48% (Insurance Companies 2.40%) an

  • Supriya Lifescience - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Jul 2026, 11:42AM Enclosed herewith is the Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018, received from RTA.

  • Supriya Lifescience - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Jul 2026, 11:42AM Supriya Lifescience Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Supriya Lifescience - General Updates

    4 Jul 2026, 10:35AM Supriya Lifescience Limited has informed the Exchange about General Updates

  • Supriya Lifescience - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.

    4 Jul 2026, 5:20AM Enclosed herewith is the intimation for submission under Regulation 30 of SEBI (LODR) Regulations, 2015.

  • Supriya Lifescience - Disclosure under SEBI Takeover Regulations

    29 Jun 2026, 4:17PM Satish Waman Wagh has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial

  • Supriya Lifescience - General Updates

    23 Jun 2026, 5:26PM Supriya Lifescience Limited has informed the Exchange about General Updates

  • Supriya Lifescience - Email Communication To Shareholders Regarding Dividend Taxation Provisions.

    23 Jun 2026, 5:25PM Email Communication to Shareholders regarding Dividend Taxation Provisions.

  • Supriya Lifescience - Trading Window

    20 Jun 2026, 4:52PM Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Jun 2026, 5:41PM Intimation of Investor/Analyst call is enclosed.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Jun 2026, 5:41PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Jun 2026, 4:10PM Supriya Lifescience Limited has informed the Exchange about Transcript

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    2 Jun 2026, 4:13PM Earnings Call Transcript is enclosed herewith.

  • Supriya Life

    29 Sep 2022 , 11:11AM The company gets European drug body's approval for antihistamine drug. Diphenhydramine Hydrochloride is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms – Positive read through for the stock.

  • Supriya Life gets European drug body's approval for antihistamine drug

    29 Sep 2022 , 9:41AM EDQM grants Certification of Suitability for Diphenhydramine Hydrochloride, API in AntiHistamine therapy
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Supriya Lifescience Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 1197.733 996.76 815.368 716.083 636.983
Liabilities 1197.733 996.76 815.368 716.083 636.983
Equity 16.097 16.097 16.097 16.097 16.097
Gross Profit 294.048 260.796 172.976 128.897 213.984
Net Profit 209.12 187.958 119.114 89.857 151.81
Cash From Operating Activities 185.769 164.675 113.307 66.187 48.801
NPM(%) 25.25 26.98 20.88 19.49 28.64
Revenue 827.875 696.485 570.37 460.938 530.049
Expenses 533.827 435.689 397.394 332.041 316.065
ROE(%) 17.11 15.38 9.74 7.35 12.42

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
04 Sep 2026 1 50 0 807.25
04 Sep 2025 1 50 0 729.7
20 Sep 2024 0.8 40 0 363.1
15 Sep 2023 0.6 30 0 256.65
01 Sep 2022 0.6 30 0 378.15

Peers

Other companies within the same industry or sector that are comparable to Supriya Lifescience Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 871.70 -2.92 22.05 456.23 -26.19 0.57
Lotus Eye Hospital and Institute Ltd 108.77 -0.28 1553.86 1662.46 0.39 0.00
Vaishali Pharma Ltd 8.03 -0.37 25.09 10429.14 15.42 0.00
Astec Lifesciences Ltd 562.40 0.30 0.00 1781.23 -363.14 0.00

Company Info

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022-Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'.2024-"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". -Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.2025-Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years-Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022-Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'.2024-"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". -Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.2025-Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years-Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

Parent Organisation

Supriya Lifescience Ltd.

Founded

26/03/2008

Managing Director

Ms.Saloni Satish Wagh

NSE Symbol

SUPRIYAEQ

FAQ